Ask a research question about Graves' Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Graves' Disease
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-04-30T12:00:00Z'
category: Endocrine Disorder
parents:
- Autoimmune Disease
- Thyroid Disorder
inheritance:
- name: Polygenic inheritance
inheritance_term:
preferred_term: Polygenic inheritance
term:
id: HP:0010982
label: Polygenic inheritance
description: >-
Graves disease has a complex, polygenic inheritance pattern with contributions
from HLA-DRB1, CTLA4, PTPN22, CD40, TSHR, and FCRL3 loci interacting with
environmental factors.
evidence:
- reference: PMID:30484670
supports: SUPPORT
snippet: "Within HLA, some variants of the DRB1, DQA1 and DQB1 genes appear to be possible predictors of the development and recurrence of Graves' disease."
explanation: Multiple genetic loci contribute to Graves disease susceptibility, consistent with polygenic inheritance.
prevalence:
- population: Global
percentage: 0.5-1
evidence:
- reference: PMID:34122333
reference_title: "Hyperthyroidism Prevalence in China After Universal Salt Iodization."
supports: PARTIAL
snippet: After two decades of USI, the prevalence of overt hyperthyroidism (OH), Graves'' disease (GD), severe subclinical hyperthyroidism (severe SCH), and mild subclinical hyperthyroidism (mild SCH) in mainland China was 0.78%, 0.53%, 0.22%, and 0.22%, respectively.
explanation: The prevalence of Graves' Disease in mainland China is reported as 0.53%, which falls within the 0.5-1% range. However, this data is specific to mainland China and may not represent a global prevalence.
- reference: PMID:24126481
supports: SUPPORT
snippet: "Graves disease is an autoimmune disorder characterized by goitre, hyperthyroidism and, in 25% of patients, Graves ophthalmopathy."
explanation: Comprehensive review confirming Graves disease as the most common cause of hyperthyroidism globally.
pathophysiology:
- name: Autoantibody Production
description: The immune system produces thyroid-stimulating immunoglobulins (TSIs) that mimic the activity of thyroid-stimulating hormone (TSH), leading to an overactive thyroid.
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
- preferred_term: T cell
term:
id: CL:0000084
label: T cell
biological_processes:
- preferred_term: cAMP-mediated signaling
term:
id: GO:0141156
label: cAMP/PKA signal transduction
locations:
- preferred_term: thyroid gland
term:
id: UBERON:0002046
label: thyroid gland
evidence:
- reference: PMID:37047805
reference_title: "Characterizing the Interplay of Lymphocytes in Graves' Disease."
supports: PARTIAL
snippet: The disease is primarily mediated by B cells, which produce autoantibodies against the thyroid-stimulating hormone receptor (TSHR), chronically stimulating it and leading to high levels of thyroid hormones in the body.
explanation: The literature confirms the role of B cells in producing autoantibodies that stimulate the thyroid, but it does not explicitly mention thyroid-stimulating immunoglobulins (TSIs).
- reference: PMID:1356056
reference_title: "Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies."
supports: PARTIAL
snippet: In the former, there is overactivity of the thyroid due to the action of a thyroid-stimulating antibody (TSAb).
explanation: The literature confirms that thyroid-stimulating antibodies (TSAb) cause overactivity of the thyroid, but it does not explicitly mention T cells or the term 'thyroid-stimulating immunoglobulins (TSIs)'.
- reference: PMID:6129186
reference_title: "Thyroid-stimulating immunoglobulins."
supports: PARTIAL
snippet: The presence of thyroid-stimulating immunoglobulins in patients with Graves' disease is well established.
explanation: The literature confirms the presence of thyroid-stimulating immunoglobulins (TSIs) in Graves' disease but does not explicitly mention the involvement of T cells.
- reference: PMID:9534029
reference_title: "The pathogenesis of Graves' disease."
supports: SUPPORT
snippet: Graves' disease, one of the autoimmune thyroid diseases, is caused by the production of IgG autoantibodies directed against the thyrotropin receptor. These antibodies bind to and activate the receptor, causing the autonomous production of thyroid hormones.
explanation: The literature confirms that IgG autoantibodies (which include TSIs) activate the thyrotropin receptor, leading to overactive thyroid function.
- reference: PMID:14654350
reference_title: "Thyroid-stimulating hormone receptor and its role in Graves' disease."
supports: SUPPORT
snippet: In Graves' disease, thyroid-stimulating autoantibodies can mimic TSH action and stimulate thyroid cells. This leads to hyperthyroidism and abnormal overproduction of thyroid hormone.
explanation: The literature confirms that thyroid-stimulating autoantibodies mimic TSH action, leading to an overactive thyroid.
- name: Thyroid Overactivity
description: Excessive stimulation of the thyroid gland results in increased production of thyroid hormones (thyroxine, T4, and triiodothyronine, T3).
downstream:
- target: Hyperthyroidism
biological_processes:
- preferred_term: thyroid hormone biosynthetic process
term:
id: GO:0006590
label: thyroid hormone generation
locations:
- preferred_term: thyroid gland
term:
id: UBERON:0002046
label: thyroid gland
evidence:
- reference: PMID:14654350
reference_title: "Thyroid-stimulating hormone receptor and its role in Graves' disease."
supports: SUPPORT
snippet: In Graves' disease, thyroid-stimulating autoantibodies can mimic TSH action and stimulate thyroid cells. This leads to hyperthyroidism and abnormal overproduction of thyroid hormone.
explanation: The reference supports the statement that excessive stimulation of the thyroid gland in Graves' Disease results in increased production of thyroid hormones (T4 and T3), leading to hyperthyroidism.
- reference: PMID:17380820
reference_title: "Hyperthyroidism."
supports: SUPPORT
snippet: Common causes are Graves' disease, toxic multinodular goitre and toxic solitary nodule. Excess thyroid hormones in the circulation are also found in thyroiditis (hormone leakage) and excess exogenous thyroxine intake.
explanation: The reference supports the statement by listing Graves' disease as a common cause of hyperthyroidism due to the increased production of thyroid hormones.
- reference: PMID:9292944
reference_title: "Increased production of B-cell growth factor by T lymphocytes in Graves' thyroid: possible role of CD4+ CD29+ cells."
supports: NO_EVIDENCE
snippet: BCGF production by T cells from the thyroid or peripheral blood of Graves' patients, in the absence or presence of PHA, was significantly greater than that by peripheral T cells from healthy controls.
explanation: The reference supports the statement by indicating the role of immune cells in the thyroid gland's overactivity in Graves' disease, contributing to the excessive production of thyroid hormones.
- reference: PMID:24126481
reference_title: "Diagnosis and management of Graves disease: a global overview."
supports: SUPPORT
snippet: Graves disease is an autoimmune disorder characterized by goitre, hyperthyroidism and, in 25% of patients, Graves ophthalmopathy. The hyperthyroidism is caused by thyroid hypertrophy and stimulation of function, resulting from interaction of anti-TSH-receptor antibodies (TRAb) with the TSH receptor on thyroid follicular cells.
explanation: The reference supports the statement by describing how Graves' disease leads to hyperthyroidism through excessive stimulation of the thyroid gland, resulting in increased production of thyroid hormones.
- name: Immune System Dysregulation
description: Dysregulated immune response leads to autoimmune attacks on the thyroid gland.
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
- preferred_term: T cell
term:
id: CL:0000084
label: T cell
- preferred_term: T follicular helper cell
term:
id: CL:0002038
label: T follicular helper cell
- preferred_term: CD4-positive, alpha-beta T cell
term:
id: CL:0000624
label: CD4-positive, alpha-beta T cell
- preferred_term: regulatory T cell
term:
id: CL:0000815
label: regulatory T cell
biological_processes:
- preferred_term: B cell activation
term:
id: GO:0042113
label: B cell activation
evidence:
- reference: PMID:37047805
reference_title: "Characterizing the Interplay of Lymphocytes in Graves' Disease."
supports: SUPPORT
snippet: The disease is primarily mediated by B cells, which produce autoantibodies against the thyroid-stimulating hormone receptor (TSHR)... T cell populations are markedly distinct, including increased levels of Th17 and follicular helper T cells (Tfh), while Treg cells appear to be impaired.
explanation: This reference supports the involvement of both B cells and T cells in the dysregulated immune response leading to autoimmune attacks on the thyroid gland in Graves' disease.
- reference: PMID:37515444
reference_title: "COVID-19-induced autoimmune thyroiditis: Exploring molecular mechanisms."
supports: PARTIAL
snippet: The incidence of autoimmune thyroid diseases, such as subacute thyroiditis, Graves' disease, and Hashimoto's thyroiditis, increases in individuals with COVID-19 infection. This phenomenon may be attributed to aberrant responses of T-cell subtypes, the presence of autoantibodies, impaired regulatory cell function, and excessive production of inflammatory cytokines.
explanation: This reference supports the involvement of T cells and B cells (through autoantibodies) in the immune dysregulation associated with Graves' disease.
- reference: PMID:21850926
reference_title: "The immune system which adversely alter thyroid functions: a review on the concept of autoimmunity."
supports: SUPPORT
snippet: The autoimmunity to the thyroid gland mainly consists of Hashimato thyroiditis and Grave's disease... The thyroid stimulating hormone receptor, thyroglobuline, enzymes of thyroid hormones synthesis are targeted by autoantibodies and cell- mediated reactions.
explanation: This reference supports the role of B cells (through autoantibodies) and T cells in the autoimmune attack on the thyroid gland in Graves' disease.
- reference: PMID:24802957
reference_title: "Dendritic cells in autoimmune disorders and cancer of the thyroid."
supports: PARTIAL
snippet: Dendritic cells (DCs), considered as one of the crucial immune regulatory populations, are implicated in the immune pathology of various disorders... including Hashimoto's thyroiditis and Graves' disease.
explanation: This reference supports the involvement of immune cells in the pathology of Graves' disease, indicating immune system dysregulation.
- name: TSHR-IGF1R Receptor Crosstalk in Orbital Fibroblasts
description: In thyroid eye disease, cooperative signaling between thyrotropin receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts drives hyaluronan production, adipogenesis, and tissue remodeling causing proptosis.
cell_types:
- preferred_term: fibroblast
term:
id: CL:0000057
label: fibroblast
biological_processes:
- preferred_term: cAMP-mediated signaling
term:
id: GO:0141156
label: cAMP/PKA signal transduction
- preferred_term: MAPK cascade
term:
id: GO:0000165
label: MAPK cascade
- preferred_term: phosphatidylinositol 3-kinase signaling
term:
id: GO:0043491
label: phosphatidylinositol 3-kinase/protein kinase B signal transduction
- preferred_term: adipocyte differentiation
term:
id: GO:0045444
label: fat cell differentiation
- preferred_term: hyaluronan biosynthetic process
term:
id: GO:0030213
label: hyaluronan biosynthetic process
- preferred_term: extracellular matrix organization
term:
id: GO:0030198
label: extracellular matrix organization
locations:
- preferred_term: orbit
term:
id: UBERON:0001697
label: orbit of skull
- preferred_term: extraocular muscle
term:
id: UBERON:0001601
label: extra-ocular muscle
notes: TSHR-IGF1R crosstalk explains the pathophysiology of Graves' orbitopathy (thyroid eye disease) affecting 25-50% of patients.
- name: Germinal Center Autoantibody Production
description: CD40-CD40L interactions between T follicular helper cells and B cells drive germinal center formation and affinity maturation of TRAb-producing B cells with oligoclonal expansion and epitope spreading.
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
- preferred_term: T follicular helper cell
term:
id: CL:0002038
label: T follicular helper cell
biological_processes:
- preferred_term: B cell activation
term:
id: GO:0042113
label: B cell activation
- preferred_term: adaptive immune response
term:
id: GO:0002250
label: adaptive immune response
- preferred_term: germinal center formation
term:
id: GO:0002467
label: germinal center formation
locations:
- preferred_term: thyroid gland
term:
id: UBERON:0002046
label: thyroid gland
notes: Intrathyroidal germinal centers are a hallmark feature of Graves' disease pathophysiology.
phenotypes:
- category: Endocrine
name: Hyperthyroidism
frequency: VERY_FREQUENT
diagnostic: true
sequelae:
- target: Weight Loss
- target: Increased Appetite
- target: Heat Intolerance
- target: Sweating
evidence:
- reference: PMID:2451239
reference_title: "Graves' disease. Manifestations and therapeutic options."
supports: SUPPORT
snippet: Graves' disease is the most common cause of hyperthyroidism. Clinical features include thyroid enlargement, eye signs, tachycardia, heat intolerance, emotional lability, weight loss, and hyperkinesis.
explanation: The literature supports that Graves' Disease is an endocrine disorder that frequently causes hyperthyroidism and has sequelae such as weight loss and heat intolerance.
- reference: PMID:37725590
reference_title: "Fracture Incidence in Graves' Disease: A Population-Based Study."
supports: SUPPORT
snippet: Graves' disease (GD) is an autoimmune disease, and it is the most common cause of hyperthyroidism.
explanation: This statement corroborates that Graves' Disease frequently causes hyperthyroidism.
phenotype_term:
preferred_term: Hyperthyroidism
term:
id: HP:0000836
label: Hyperthyroidism
- category: Ocular
name: Exophthalmos (Proptosis)
frequency: FREQUENT
notes: Bulging of the eyes due to inflammation and tissue buildup behind the eyes.
evidence:
- reference: PMID:34243871
reference_title: "Extrathyroidal Manifestations of Thyroid Disease: Graves Eye Disease."
supports: PARTIAL
snippet: In approximately 25% of patients, an inflammatory condition, Graves eye disease (GED), affects the orbital soft tissues. About 60% of patients develop mild symptoms including fat expansion and inflammation of the levator muscle complex with resultant proptosis, eyelid retraction, and exposure of the globe.
explanation: The literature indicates that proptosis occurs in a subset of patients with Graves' disease, but it does not support that it is a frequent occurrence for all patients.
- reference: PMID:35315985
reference_title: "Proptosis is associated with thiol-disulfide in patients with Graves' ophthalmopathy."
supports: SUPPORT
snippet: Graves' ophthalmopathy (GO) is a vision-threatening finding observed in approximately half of Graves' disease patients. The pathophysiology of GO is unclear, and one of the suspected factors is oxidative stress.
explanation: This reference supports the statement by indicating that proptosis is a frequent finding in about half of Graves' disease patients.
- reference: PMID:34951116
reference_title: "Pediatric Graves' orbitopathy: a multicentre study."
supports: PARTIAL
snippet: Clinical findings included proptosis (n = 97; 84.3%), eyelid retraction (n = 77; 67%) and diplopia (n = 13; 11.3%).
explanation: This reference supports the statement by indicating a high frequency (84.3%) of proptosis in pediatric Graves' orbitopathy, which aligns with the frequency aspect of the statement.
- reference: PMID:32976333
reference_title: "Periphlebitis of the Superior Ophthalmic Vein."
supports: PARTIAL
snippet: Superior ophthalmic vein periphlebitis is a rare form of orbital inflammation presenting with proptosis and motility restriction yet few inflammatory signs.
explanation: This reference mentions proptosis in the context of a rare form of orbital inflammation associated with Graves' disease, but does not provide enough information to support the frequency aspect of the statement.
- reference: PMID:20181974
reference_title: "Graves' ophthalmopathy."
supports: PARTIAL
snippet: Graves' ophthalmopathy, also called Graves' orbitopathy, is a potentially sight-threatening ocular disease... Generally occurring in patients with hyperthyroidism or a history of hyperthyroidism due to Graves' disease.
explanation: This reference supports the statement by indicating that ocular manifestations, including proptosis, are common in Graves' disease.
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0000520 | Proptosis | Frequent (79-30%)"
explanation: Orphanet classifies proptosis as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Proptosis
term:
id: HP:0000520
label: Proptosis
- category: Endocrine
name: Goiter
frequency: FREQUENT
notes: Enlargement of the thyroid gland, often visible as a swelling in the neck.
evidence:
- reference: PMID:2451239
reference_title: "Graves' disease. Manifestations and therapeutic options."
supports: SUPPORT
snippet: Graves' disease is the most common cause of hyperthyroidism. Clinical features include thyroid enlargement...
explanation: The literature indicates that Graves' disease frequently results in thyroid enlargement, which aligns with the statement that goiter is a frequent manifestation of Graves' disease.
- reference: PMID:4886698
reference_title: "Goiter."
supports: NO_EVIDENCE
snippet: Goiter.
explanation: The reference is titled 'Goiter' but does not provide specific information about its frequency in Graves' disease.
- reference: PMID:22632361
reference_title: "Evaluating Graves' orbitopathy."
supports: NO_EVIDENCE
snippet: Graves' Orbitopathy (GO) is an immune-mediated disorder causing inflammation and expansion of orbital fat and muscle...
explanation: Although this reference primarily discusses Graves' Orbitopathy, it supports the context that Graves' disease involves immune-mediated disorders affecting the thyroid, which can lead to goiter.
- reference: PMID:22112923
reference_title: "Graves' disease following subacute thyroiditis."
supports: NO_EVIDENCE
snippet: Among them, subacute thyroiditis and Graves' disease accounted for 918 patients (3.6%) and 4,617 patients (18.2%), respectively.
explanation: The literature mentions the significant prevalence of Graves' disease, which often includes thyroid enlargement as a symptom, supporting the statement.
- reference: PMID:37152963
reference_title: "Graves' disease as a driver of depression: a mechanistic insight."
supports: SUPPORT
snippet: Graves' disease (GD) is characterized by diffuse enlargement and overactivity of the thyroid gland...
explanation: This reference directly supports the statement by mentioning that Graves' disease is characterized by diffuse enlargement of the thyroid gland, which is synonymous with goiter.
- reference: PMID:14605602
reference_title: "Thyroid cancer yield in patients with Graves' disease."
supports: PARTIAL
snippet: Several studies have demonstrated both an increased incidence of nodules and of thyroid cancer in patients with Graves' disease...
explanation: The reference indicates that thyroid enlargement (goiter) is a frequent occurrence in Graves' disease, supporting the statement.
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0000853 | Goiter | Frequent (79-30%)"
explanation: Orphanet classifies goiter as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Goiter
term:
id: HP:0000853
label: Goiter
- category: Cardiovascular
name: Sinus Tachycardia
frequency: VERY_FREQUENT
notes: Increased heart rate, commonly experienced as palpitations.
evidence:
- reference: PMID:32402541
reference_title: "Impact of surgery versus medical management on cardiovascular manifestations in Graves disease."
supports: SUPPORT
snippet: Tachyarrhythmias, including atrial fibrillation and tachycardia, improved in 85.9% of patients in the surgical group vs 66% in the medical group (P = .01).
explanation: The study shows that tachyarrhythmias, which include tachycardia, are common in patients with Graves' disease and improve with treatment.
- reference: PMID:33749695
reference_title: "Heart failure from thyrotoxicosis due to Graves' disease."
supports: PARTIAL
snippet: She was hypoxic and tachycardic and was extensively investigated as well as aggressively treated.
explanation: The case report mentions a patient with Graves' disease experiencing tachycardia, supporting the statement that tachycardia is a frequent cardiovascular manifestation of Graves' disease.
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0011703 | Sinus tachycardia | Very frequent (99-80%)"
explanation: Orphanet classifies sinus tachycardia as very frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Sinus tachycardia
term:
id: HP:0011703
label: Sinus tachycardia
- category: Musculoskeletal
name: Tremor
frequency: FREQUENT
notes: Fine shaking, particularly in the hands.
evidence:
- reference: PMID:36940965
reference_title: "The characteristics of Grave's disease in children and adolescent patients in Al-Madinah Al-Munawwarah: A retrospective chart review."
supports: SUPPORT
snippet: Tremors (29.3%) were the most common manifestations.
explanation: The literature indicates that tremors are a common manifestation in patients with Graves' Disease.
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0001337 | Tremor | Frequent (79-30%)"
explanation: Orphanet classifies tremor as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Tremor
term:
id: HP:0001337
label: Tremor
- category: Psychiatric
name: Anxiety
frequency: FREQUENT
evidence:
- reference: PMID:38215285
reference_title: "Psychiatric complications in Graves' disease."
supports: SUPPORT
snippet: 'Depression scores and anxiety scores were higher in patients compared to controls both during hyperthyroidism (depression (median (IQR): 7.5 (5.0-9.5) vs 1.0 (0.5-2.5) P < 0.001), anxiety: 7.7 (5.0-11) vs 2.5 (1.0-4.0) P < 0.001) and after treatment (depression: 2.5 (1.5-5.0) vs 1.5 (0.5-3.5) P < 0.05), anxiety: 4.0 (2.5-7.5) vs 3.0 (1.5-5.0) P < 0.05).'
explanation: The study indicates that anxiety scores are significantly higher in patients with Graves' disease compared to controls, both during hyperthyroidism and after treatment, supporting the statement that anxiety is a frequent psychiatric complication of Graves' disease.
phenotype_term:
preferred_term: Anxiety
term:
id: HP:0000739
label: Anxiety
- category: Psychiatric
frequency: FREQUENT
name: Irritability
evidence:
- reference: PMID:38644701
reference_title: "Examination of quality of life and psychiatric symptoms in childhood Graves' disease."
supports: PARTIAL
snippet: In children with GD, irritability, oppositional defiant, and conduct disorder symptoms have been detected.
explanation: The study found that children with Graves' Disease exhibited symptoms of irritability, supporting the statement that irritability is a frequent psychiatric symptom in GD.
- reference: PMID:36853810
reference_title: "Hyperthyroidism and depression: a clinical case of atypical thyrotoxicosis manifestation."
supports: PARTIAL
snippet: The common view is that clinical hypothyroidism is associated with depressive symptoms, whereas the psychiatric manifestations of hyperthyroidism are agitation, emotional lability, hyperexcitability, occasionally accompanied by angry outbursts, and euphoria.
explanation: The literature supports the association of hyperthyroidism, which is a characteristic of Graves' Disease, with psychiatric symptoms including irritability.
- reference: PMID:37224080
reference_title: "The relationship between mental fatigue, depression, and cognition in Graves' disease."
supports: PARTIAL
snippet: Mental fatigue, depression, anxiety, and cognitive complaints are common in Graves' disease (GD).
explanation: This reference supports the presence of psychiatric symptoms in GD, including emotional distress which can encompass irritability.
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0000737 | Irritability | Frequent (79-30%)"
explanation: Orphanet classifies irritability as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Irritability
term:
id: HP:0000737
label: Irritability
- category: Dermatologic
frequency: VERY_RARE
name: Pretibial Myxedema
notes: Swelling and thickening of the skin, usually on the shins.
evidence:
- reference: PMID:8309359
reference_title: "Dermopathy of Graves disease (pretibial myxedema). Review of 150 cases."
supports: SUPPORT
snippet: Pretibial myxedema is an uncommon manifestation of Graves disease...
explanation: The literature states that pretibial myxedema is an uncommon manifestation of Graves disease, aligning with the statement that it occurs occasionally.
- reference: PMID:34047397
reference_title: "Local immune microenvironment of skin may play an important role in the development of pretibial myxedema."
supports: PARTIAL
snippet: Pretibial myxedema (PTM)... is almost always associated with Graves' disease (GD).
explanation: The literature confirms the association of pretibial myxedema with Graves' disease, supporting its classification as an occasional dermatologic manifestation.
- reference: PMID:37193106
reference_title: "Worsening of pretibial myxedema following radioiodine treatment for hyperthyroid Graves' disease."
supports: PARTIAL
snippet: Worsening of pretibial myxedema following radioiodine treatment for hyperthyroid Graves' disease.
explanation: This reference supports the occurrence of pretibial myxedema in the context of Graves' disease.
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0200028 | Pretibial myxedema | Very rare (<4-1%)"
explanation: Orphanet classifies pretibial myxedema as very rare in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Pretibial Myxedema
term:
id: HP:0200028
label: Pretibial myxedema
- category: Systemic
name: Weight Loss
frequency: FREQUENT
evidence:
- reference: PMID:2451239
supports: SUPPORT
snippet: "Clinical features include thyroid enlargement, eye signs, tachycardia, heat intolerance, emotional lability, weight loss, and hyperkinesis."
explanation: Weight loss is listed among the cardinal clinical features of Graves disease.
phenotype_term:
preferred_term: Weight Loss
term:
id: HP:0001824
label: Weight loss
- category: Systemic
name: Increased Appetite
frequency: FREQUENT
evidence:
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0002591 | Polyphagia | Frequent (79-30%)"
explanation: Orphanet classifies polyphagia as frequent in pediatric-onset Graves disease.
- reference: PMID:20351569
supports: SUPPORT
snippet: "Steatorrhea is due to hyperphagia and stimulation of the adrenergic system."
explanation: Hyperphagia (increased appetite) is a recognized feature of thyrotoxicosis contributing to GI manifestations.
phenotype_term:
preferred_term: Increased Appetite
term:
id: HP:0002591
label: Polyphagia
- category: Systemic
name: Heat Intolerance
frequency: FREQUENT
evidence:
- reference: PMID:2451239
supports: SUPPORT
snippet: "Clinical features include thyroid enlargement, eye signs, tachycardia, heat intolerance, emotional lability, weight loss, and hyperkinesis."
explanation: Heat intolerance is listed among the cardinal clinical features of Graves disease.
phenotype_term:
preferred_term: Heat Intolerance
term:
id: HP:0002046
label: Heat intolerance
- category: Systemic
name: Sweating
frequency: FREQUENT
evidence:
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0000975 | Hyperhidrosis | Frequent (79-30%)"
explanation: Orphanet classifies hyperhidrosis as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Sweating
term:
id: HP:0000975
label: Hyperhidrosis
- category: Ocular
name: Diplopia
frequency: OCCASIONAL
notes: Double vision caused by extraocular muscle enlargement and fibrosis in thyroid eye disease.
evidence:
- reference: PMID:34951116
supports: SUPPORT
snippet: "Clinical findings included proptosis (n = 97; 84.3%), eyelid retraction (n = 77; 67%) and diplopia (n = 13; 11.3%)."
explanation: Diplopia was observed in 11.3% of pediatric Graves orbitopathy patients, consistent with occasional frequency.
phenotype_term:
preferred_term: Diplopia
term:
id: HP:0000651
label: Diplopia
- category: Ocular
name: Eyelid retraction
frequency: FREQUENT
notes: Common ocular manifestation in thyroid eye disease, present in approximately 67% of patients with Graves orbitopathy.
evidence:
- reference: PMID:34951116
supports: SUPPORT
snippet: "Clinical findings included proptosis (n = 97; 84.3%), eyelid retraction (n = 77; 67%) and diplopia (n = 13; 11.3%)."
explanation: Eyelid retraction was present in 67% of pediatric Graves orbitopathy patients.
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0000492 | Abnormal eyelid morphology | Frequent (79-30%)"
explanation: Orphanet classifies abnormal eyelid morphology (including retraction) as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Eyelid retraction
term:
id: HP:0500043
label: Eyelid retraction
- category: Endocrine
name: Thyroid acropachy
frequency: VERY_RARE
notes: Rare manifestation characterized by digital clubbing and periosteal bone formation.
- category: Cardiovascular
name: Atrial fibrillation
frequency: OCCASIONAL
notes: Occurs in approximately 10% of patients, more common in older adults.
evidence:
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0005110 | Atrial fibrillation | Occasional (29-5%)"
explanation: Orphanet classifies atrial fibrillation as occasional in pediatric-onset Graves disease.
- reference: PMID:32402541
supports: SUPPORT
snippet: "Tachyarrhythmias, including atrial fibrillation and tachycardia, improved in 85.9% of patients in the surgical group vs 66% in the medical group (P = .01)."
explanation: Atrial fibrillation is a recognized tachyarrhythmia in Graves disease patients that improves with treatment.
phenotype_term:
preferred_term: Atrial fibrillation
term:
id: HP:0005110
label: Atrial fibrillation
- category: Psychiatric
name: Emotional Lability
frequency: FREQUENT
description: Rapid mood changes and emotional instability characteristic of thyrotoxicosis.
evidence:
- reference: PMID:2451239
supports: SUPPORT
snippet: "Clinical features include thyroid enlargement, eye signs, tachycardia, heat intolerance, emotional lability, weight loss, and hyperkinesis."
explanation: Emotional lability is listed among the cardinal clinical features of Graves disease.
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0000712 | Emotional lability | Frequent (79-30%)"
explanation: Orphanet classifies emotional lability as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Emotional lability
term:
id: HP:0000712
label: Emotional lability
- category: Psychiatric
name: Depression
frequency: FREQUENT
description: Depressive symptoms significantly elevated in Graves disease patients compared to controls, persisting even after euthyroidism is restored.
evidence:
- reference: PMID:38215285
supports: SUPPORT
snippet: 'Depression scores and anxiety scores were higher in patients compared to controls both during hyperthyroidism (depression (median (IQR): 7.5 (5.0-9.5) vs 1.0 (0.5-2.5) P < 0.001), anxiety: 7.7 (5.0-11) vs 2.5 (1.0-4.0) P < 0.001) and after treatment (depression: 2.5 (1.5-5.0) vs 1.5 (0.5-3.5) P < 0.05), anxiety: 4.0 (2.5-7.5) vs 3.0 (1.5-5.0) P < 0.05).'
explanation: Depression scores are significantly higher in Graves disease patients both during hyperthyroidism and after treatment.
- reference: PMID:37152963
supports: SUPPORT
snippet: "Among them, depression can dramatically damage patients' quality of life, yet its prevalence in GD has not received adequate attention."
explanation: Review establishing a strong correlation between Graves disease and increased risk of depression through autoimmune, hormonal, and gut-brain axis mechanisms.
phenotype_term:
preferred_term: Depression
term:
id: HP:0000716
label: Depression
- category: Psychiatric
name: Insomnia
frequency: FREQUENT
description: Sleep disturbance driven by hypermetabolic state and sympathetic overactivation.
evidence:
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0100785 | Insomnia | Frequent (79-30%)"
explanation: Orphanet classifies insomnia as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Insomnia
term:
id: HP:0100785
label: Insomnia
- category: Cardiovascular
name: Palpitations
frequency: FREQUENT
description: Awareness of heartbeat, often the presenting complaint in Graves disease.
evidence:
- reference: PMID:36940965
supports: SUPPORT
snippet: "Exophthalmos (63.8%), neck swelling (60.3%), palpitations (46.6%), and tremors (29.3%) were the most common manifestations."
explanation: Palpitations were present in 46.6% of pediatric Graves disease patients.
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0001962 | Palpitations | Frequent (79-30%)"
explanation: Orphanet classifies palpitations as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Palpitations
term:
id: HP:0001962
label: Palpitations
- category: Gastrointestinal
name: Diarrhea
frequency: FREQUENT
description: Increased bowel motility and accelerated intestinal transit time due to thyrotoxicosis.
evidence:
- reference: PMID:20351569
supports: SUPPORT
snippet: "Transit time from mouth to cecum is accelerated, resulting in diarrhea."
explanation: Accelerated GI transit in hyperthyroidism results in diarrhea as a recognized clinical feature.
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0002014 | Diarrhea | Frequent (79-30%)"
explanation: Orphanet classifies diarrhea as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Diarrhea
term:
id: HP:0002014
label: Diarrhea
- category: Hepatic
name: Elevated Hepatic Transaminases
frequency: FREQUENT
description: Liver blood test abnormalities are common in untreated Graves disease, with approximately 60% of patients showing at least one abnormal liver test.
evidence:
- reference: PMID:33327837
supports: SUPPORT
snippet: "LBT abnormalities are common in newly diagnosed and untreated hyperthyroidism setting."
explanation: Meta-analysis of 25 studies demonstrating that liver blood test abnormalities are common in untreated hyperthyroid/Graves disease patients.
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0002910 | Elevated circulating hepatic transaminase concentration | Frequent (79-30%)"
explanation: Orphanet classifies elevated hepatic transaminases as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Elevated circulating hepatic transaminase concentration
term:
id: HP:0002910
label: Elevated circulating hepatic transaminase concentration
- category: Musculoskeletal
name: Proximal Muscle Weakness
frequency: FREQUENT
description: Thyrotoxic myopathy causing proximal muscle weakness and wasting due to thyroid hormone-mediated stimulation of muscle proteolysis.
evidence:
- reference: PMID:39297559
supports: SUPPORT
snippet: "muscle wasting is a common feature in patients with hyperthyroidism and is mainly caused by THs-dependent stimulation of muscle proteolysis"
explanation: Thyroid hormone excess stimulates muscle protein breakdown, causing the proximal muscle weakness characteristic of thyrotoxic myopathy.
phenotype_term:
preferred_term: Proximal muscle weakness
term:
id: HP:0003701
label: Proximal muscle weakness
- category: Systemic
name: Fatigue
frequency: FREQUENT
description: Fatigue and mental fatigue are common complaints in Graves disease, often persisting after restoration of euthyroidism.
evidence:
- reference: PMID:37224080
supports: SUPPORT
snippet: "Mental fatigue, depression, anxiety, and cognitive complaints are common in Graves' disease (GD)."
explanation: Mental fatigue is recognized as a common symptom of Graves disease.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
- category: Dermatologic
name: Flushing
frequency: FREQUENT
description: Cutaneous vasodilation and flushing from sympathetic overactivation and increased metabolic rate.
evidence:
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0031284 | Flushing | Frequent (79-30%)"
explanation: Orphanet classifies flushing as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Flushing
term:
id: HP:0031284
label: Flushing
- category: Reproductive
name: Oligomenorrhea
frequency: OCCASIONAL
description: Menstrual irregularities, most commonly hypomenorrhea and oligomenorrhea, affecting approximately 21.5% of thyrotoxic women.
evidence:
- reference: PMID:11119728
supports: SUPPORT
snippet: "we found that only 21.5% of 214 thyrotoxic patients had some type of menstrual disturbance, compared to 50 to 60% in some older series. The most common manifestations are hypomenorrhea and oligomenorrhea."
explanation: Krassas et al. documented menstrual disturbances in 21.5% of thyrotoxic patients with oligomenorrhea being one of the most common manifestations.
phenotype_term:
preferred_term: Oligomenorrhea
term:
id: HP:0000876
label: Oligomenorrhea
- category: Psychiatric
name: Hyperactivity
frequency: FREQUENT
description: Psychomotor hyperactivity and hyperkinesis are cardinal features of thyrotoxicosis.
evidence:
- reference: PMID:2451239
supports: SUPPORT
snippet: "Clinical features include thyroid enlargement, eye signs, tachycardia, heat intolerance, emotional lability, weight loss, and hyperkinesis."
explanation: Hyperkinesis (hyperactivity) is listed among the cardinal clinical features of Graves disease.
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0000752 | Hyperactivity | Frequent (79-30%)"
explanation: Orphanet classifies hyperactivity as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Hyperactivity
term:
id: HP:0000752
label: Hyperactivity
- category: Systemic
name: Polydipsia
frequency: FREQUENT
description: Increased thirst driven by hypermetabolic state and increased fluid losses.
evidence:
- reference: ORPHA:525731
supports: SUPPORT
snippet: "HP:0001959 | Polydipsia | Frequent (79-30%)"
explanation: Orphanet classifies polydipsia as frequent in pediatric-onset Graves disease.
phenotype_term:
preferred_term: Polydipsia
term:
id: HP:0001959
label: Polydipsia
biochemical:
- name: Free Thyroxine (T4)
presence: Increased
context: Indicates hyperthyroidism
evidence:
- reference: PMID:2816972
reference_title: "Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms."
supports: PARTIAL
snippet: We examined 25 patients with untreated, newly diagnosed Graves' disease using the Hyperthyroid Symptom Scale (HSS) and serum levels of thyroxine (T4), triiodothyronine (T3) relative insulin area (RIA), and estimates of free thyroxine index (FTI).
explanation: The study confirms that patients with untreated, newly diagnosed Graves' disease have elevated serum levels of thyroxine (T4).
- reference: PMID:30487326
reference_title: "[Secondary osteoporosis. Hyperthyroidism.]."
supports: PARTIAL
snippet: Thyrotoxicosis, commonly seen in a condition with Graves' disease, causes increased bone absorption and results in osteoporosis with increased bone turnover.
explanation: Thyrotoxicosis, which is associated with Graves' disease, implies increased levels of thyroid hormones including free thyroxine (T4).
- reference: PMID:3558731
reference_title: "Thyroxine and 3,5,3'-triiodothyronine content of thyroglobulin in thyroid needle aspirates in hyperthyroidism and hypothyroidism."
supports: NO_EVIDENCE
snippet: Thyroglobulin (Tg) was obtained by fine needle aspiration from patients with untreated hyperthyroidism due to Graves' disease...both untreated hyperthyroidism and untreated hypothyroidism were characterized by Tg with a normal T4 but a relatively high T3 content.
explanation: This reference mentions untreated hyperthyroidism due to Graves' disease and elevated levels of thyroid hormones including T4.
- reference: PMID:7527990
reference_title: "Thyroxine excess and pregnancy."
supports: PARTIAL
snippet: Hyperthyroidism occurring during pregnancy is usually due to Graves' disease and must be treated to prevent congenital anomalies, low birth weight and premature labour.
explanation: Hyperthyroidism due to Graves' disease during pregnancy indicates elevated levels of thyroid hormones including free thyroxine (T4).
- name: Free Triiodothyronine (T3)
presence: Increased
context: Indicates hyperthyroidism
evidence:
- reference: PMID:2816972
reference_title: "Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms."
supports: PARTIAL
snippet: We examined 25 patients with untreated, newly diagnosed Graves'' disease using the Hyperthyroid Symptom Scale (HSS) and serum levels of thyroxine (T4), triiodothyronine (T3) relative insulin area (RIA), and estimates of free thyroxine index (FTI).
explanation: The study involves measuring serum levels of triiodothyronine (T3) in patients with Graves' disease, indicating its relevance to hyperthyroidism.
- reference: PMID:6894450
reference_title: "Triiodothyronine generation from thyroxine in human thyroid: enhanced conversion in Graves' thyroid tissue."
supports: PARTIAL
snippet: Conversion of T4 to T3 was observed in two of three tumor tissues studied and was markedly enhanced in Graves' thyroid tissues (mean +/- SE, 11.9 +/- 2.0 pmol/mg protein.min) compared to that of normal thyroid tissues (3.2 +/- 0.6 pmol/mg protein.min; P less than 0.01).
explanation: This study shows enhanced conversion of T4 to T3 in Graves' thyroid tissues, supporting the statement that Graves' Disease indicates increased levels of Free Triiodothyronine (T3).
- reference: PMID:32493403
reference_title: "Fetal goiter identified in a pregnant woman with triiodothyronine-predominant graves' disease: a case report."
supports: PARTIAL
snippet: Approximately 10% of all Graves'' disease cases are triiodothyronine (T3)-predominant. T3-predominance is characterized by higher T3 levels than thyroxine (T4) levels.
explanation: The study mentions T3-predominant Graves' disease cases, which are characterized by higher T3 levels, supporting the statement.
- reference: PMID:8565219
reference_title: "Clinical usage recommendations and analytic performance goals for total and free triiodothyronine measurements."
supports: PARTIAL
snippet: The major clinical role for total triiodothyronine (TT3) and (or) free T3 (FT3) is the assessment of hyperthyroidism in patients with suppressed sensitive thyrotropin (sTSH) concentrations.
explanation: The statement is supported as the clinical role of free T3 measurements is to assess hyperthyroidism, which is a common manifestation of Graves' Disease.
- name: Thyroid-Stimulating Hormone (TSH)
presence: Decreased
context: Indicates feedback suppression due to high levels of thyroid hormones
evidence:
- reference: PMID:25864995
reference_title: "Thyroid stimulating hormone suppression post-therapy in patients with Graves' disease: a systematic review of pathophysiology and clinical data."
supports: SUPPORT
snippet: 'BACKGROUND: Post-treatment hypothyroidism is common in Graves'' disease, and clinical guidelines recommend monitoring for it; however, thyroid stimulating hormone (TSH) can remain suppressed in these patients following treatment.'
explanation: The literature indicates that TSH levels can remain suppressed in patients with Graves' disease, which aligns with the statement that high levels of thyroid hormones in Graves' disease lead to feedback suppression of TSH.
- reference: PMID:27936530
reference_title: "Endocrinology Update: Thyroid Disorders."
supports: PARTIAL
snippet: This level usually is elevated in patients with hypothyroidism and low in patients with hyperthyroidism. ... Graves disease is the most common etiology in developed countries.
explanation: The literature states that TSH levels are low in patients with hyperthyroidism, including those with Graves' disease, supporting the statement about decreased TSH levels due to feedback suppression.
- reference: PMID:19631028
reference_title: "Thyroid-stimulating hormone, thyroid hormones, and bone loss."
supports: PARTIAL
snippet: Evidence using mice lacking the thyroid hormone receptors alpha and beta establishes a role for thyroid hormones in regulating bone remodeling but does not exclude an independent action of thyroid-stimulating hormone (TSH), levels of which are low in hyperthyroid states.
explanation: The literature mentions that TSH levels are low in hyperthyroid states, which includes Graves' disease, supporting the statement about decreased TSH levels due to feedback suppression.
- name: Thyroid-Stimulating Immunoglobulins (TSI)
presence: Positive
context: Confirms autoimmune etiology
evidence:
- reference: PMID:34331946
reference_title: "Clinical efficacy of thyroid-stimulating immunoglobulin detection for diagnosing Graves' disease and predictors of responsiveness to methimazole."
supports: SUPPORT
snippet: As thyroid-stimulating immunoglobulins (TSI) are a sign of Graves' disease (GD), measuring TSI titers is becoming increasingly important for GD diagnosis.
explanation: The presence of TSI is indicative of Graves' Disease, confirming its autoimmune etiology.
- reference: PMID:2888784
reference_title: "Toxic multinodular goiter: a variant of autoimmune hyperthyroidism."
supports: SUPPORT
snippet: All patients with active Graves' disease (n = 47) had detectable serum TSI activity.
explanation: TSI activity is present in patients with Graves' Disease, supporting its autoimmune nature.
- reference: PMID:6129186
reference_title: "Thyroid-stimulating immunoglobulins."
supports: SUPPORT
snippet: The presence of thyroid-stimulating immunoglobulins in patients with Graves' disease is well established.
explanation: The established presence of TSI in Graves' Disease patients supports its autoimmune etiology.
- reference: PMID:23276963
reference_title: "The autoimmunity in Graves's disease."
supports: PARTIAL
snippet: Earlier studies have demonstrated the autoimmune response plays a dominant role in the development of GD.
explanation: The autoimmune response, including the presence of TSI, is crucial for the development of Graves' Disease.
genetic:
- name: HLA-DRB1
association: Risk Factor
notes: Major HLA class II susceptibility locus; mediates antigen presentation of TSHR peptides to autoreactive T cells.
evidence:
- reference: PMID:30484670
reference_title: "Genetic predictors of the development and recurrence of Graves' disease."
supports: SUPPORT
snippet: Within HLA, some variants of the DRB1, DQA1 and DQB1 genes appear to be possible predictors of the development and recurrence of Graves' disease.
explanation: This study suggests that variants within the HLA region, including DRB1 (which encompasses HLA-DR3), are associated with Graves' disease, supporting the statement that HLA-DR3 is a risk factor.
- name: CTLA4
association: Risk Factor
notes: Immune checkpoint gene that modulates T cell tolerance; genetic variants increase susceptibility to Graves' disease.
evidence:
- reference: PMID:10404810
reference_title: "The development of Graves' disease and the CTLA-4 gene on chromosome 2q33."
supports: SUPPORT
snippet: An increase in frequency of the G (alanine) allele was seen in Graves' patients compared with control subjects (42% vs. 31.5%, respectively; corrected P<0.0002; odds ratio = 1.58)
explanation: This case-control and family study demonstrates that CTLA4 polymorphisms confer genetic susceptibility to Graves' disease.
- name: PTPN22
association: Risk Factor
notes: Immune regulatory phosphatase affecting T cell signaling; susceptibility locus for autoimmune disorders including Graves' disease.
evidence:
- reference: PMID:33103521
reference_title: "The Relationship between PTPN22 R620W Polymorphisms and the Susceptibility to Autoimmune Thyroid Diseases: An Updated Meta-analysis."
supports: SUPPORT
snippet: the T allele significantly increased AITD susceptibility in all genetic models involving Caucasians
explanation: This meta-analysis of 18 studies demonstrates that PTPN22 R620W polymorphism is associated with Graves' disease susceptibility.
- name: CD40
association: Risk Factor
notes: B-T costimulatory receptor required for germinal center reactions and TRAb generation.
evidence:
- reference: PMID:12593727
reference_title: "A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves' disease."
supports: SUPPORT
snippet: our results suggested that the CD40 gene was a new susceptibility gene for GD within certain families because it was both linked and associated with GD
explanation: This study mapped CD40 as a susceptibility gene for Graves' disease through linkage and association analyses.
- name: FCRL3
association: Risk Factor
notes: B cell receptor with genetic association to Graves' disease susceptibility.
- name: TSHR
association: Risk Factor
notes: Principal autoantigen; thyrotropin receptor gene variants contribute to disease susceptibility in addition to being the primary target of autoantibodies.
evidence:
- reference: PMID:27231040
reference_title: "Association between TSHR gene polymorphism and the risk of Graves' disease: a meta-analysis."
supports: SUPPORT
snippet: both TSHR rs179247A/G and rs12101255T/C polymorphism had significant association with GD
explanation: This meta-analysis demonstrates that TSHR gene polymorphisms are significantly associated with Graves' disease susceptibility across Asian, European, and South American populations.
environmental:
- name: Stress
notes: Can trigger or exacerbate symptoms.
evidence:
- reference: PMID:11453946
reference_title: "Stressful life events and Graves' disease revisited."
supports: PARTIAL
snippet: Stressful life events and Graves' disease revisited.
explanation: This reference discusses the relationship between stressful life events and Graves' disease, supporting the idea that stress can trigger or exacerbate symptoms.
- reference: PMID:9972676
reference_title: "Chronic recurrent stress due to panic disorder does not precipitate Graves' disease."
supports: REFUTE
snippet: Chronic recurrent stress due to panic disorder does not precipitate Graves' disease.
explanation: This study found that recurrent endogenous stress due to panic disorder did not precipitate Graves' hyperthyroidism, suggesting that not all forms of stress trigger or exacerbate Graves' disease.
exposure_term:
preferred_term: Psychological stress exposure
- name: Smoking
notes: Increases the risk of developing and worsening Graves’ ophthalmopathy.
evidence:
- reference: PMID:22632372
reference_title: "Prevention of Graves' ophthalmopathy."
supports: SUPPORT
snippet: Smoking is the most important risk factor for the occurrence/progression of Graves' ophthalmopathy (GO), as well as for its lower/slower response to immunosuppression.
explanation: The literature explicitly states that smoking is a significant risk factor for both the development and worsening of Graves' ophthalmopathy.
- reference: PMID:32107168
reference_title: "Graves' disease: Epidemiology, genetic and environmental risk factors and viruses."
supports: SUPPORT
snippet: Among environmental risk factors, smoking, iodine excess, selenium and vitamin D deficiency, and the occupational exposure to Agent Orange have been associated with GD.
explanation: The literature mentions smoking as an environmental risk factor associated with Graves' disease.
exposure_term:
preferred_term: Tobacco smoking exposure
term:
id: ECTO:6000029
label: exposure to tobacco smoking
diagnosis:
- name: Radioactive Iodine Uptake Test
notes: High uptake indicates hyperthyroidism.
evidence:
- reference: PMID:11444164
reference_title: "Radioiodine uptake and thyroid scintiscanning."
supports: PARTIAL
snippet: The main uses of the radioactive iodine uptake test are to identify the cause of hyperthyroidism and to aid in the selection of the I-131 dose in the treatment of hyperthyroidism.
explanation: The radioactive iodine uptake test is used to identify the cause of hyperthyroidism, which supports its use in diagnosing Graves' Disease, a common cause of hyperthyroidism.
- reference: PMID:10206194
reference_title: "Hyperthyroidism: multiple possibilities in the female patient."
supports: SUPPORT
snippet: Graves' Disease, an autoimmune disorder, demonstrates a strong female prevalence; the twenty-four hour radioiodine uptake is normal or elevated.
explanation: The radioactive iodine uptake is elevated in Graves' Disease, indicating hyperthyroidism, which supports the statement.
- reference: PMID:25257665
reference_title: "Diagnosis of pediatric hyperthyroidism: technetium 99 uptake versus thyroid stimulating immunoglobulins."
supports: PARTIAL
snippet: Uptake studies with (123)I or (99)Tc ((99m)Tc) provide accurate and rapid diagnosis but are expensive and involve radiation exposure.
explanation: Uptake studies are used for the diagnosis of hyperthyroidism, including Graves' Disease.
- name: Thyroid Ultrasound
notes: Visualizes the thyroid gland and detects abnormalities.
evidence:
- reference: PMID:16640177
reference_title: "[Sonography of the thyroid]."
supports: PARTIAL
snippet: Ultrasound is a reliable examination to detect various pathologies of the thyroid gland and it should always be combined with a sonography of the surrounding soft tissues and vessels.
explanation: The article supports the use of ultrasound in detecting various pathologies of the thyroid gland, which aligns with the statement that thyroid ultrasound visualizes the thyroid gland and detects abnormalities.
- reference: PMID:22938934
reference_title: "Imaging of thyrotoxicosis."
supports: PARTIAL
snippet: The purpose of this paper is to review the medical literature outlining the important role that ultrasonography (US) can play in the diagnosis and management of patients with hyperthyroidism.
explanation: The paper highlights the role of ultrasound in diagnosing and managing hyperthyroidism, which supports the statement regarding the use of thyroid ultrasound to detect abnormalities.
- reference: PMID:30834273
reference_title: "Standardized Uptake Value Using Thyroid Quantitative SPECT/CT for the Diagnosis and Evaluation of Graves' Disease: A Prospective Multicenter Study."
supports: NO_EVIDENCE
snippet: The volumes determined by Q.Metrix (35.65 +/- 20.56ml) of 72 subjects also positively correlated with that from ultrasound (36.67 +/- 21.00ml) with a coefficient of 0.927 (P<0.01).
explanation: This study shows that ultrasound is used to measure thyroid volume, supporting the statement that thyroid ultrasound visualizes the thyroid gland and detects abnormalities.
- reference: PMID:3279732
reference_title: "Color-flow Doppler sonography in Graves disease: \"thyroid inferno\"."
supports: SUPPORT
snippet: Color-flow Doppler sonography shows promise as a cost-effective, noninvasive technique for diagnosing Graves disease.
explanation: The use of color-flow Doppler sonography, a form of ultrasound, in diagnosing Graves' disease supports the statement about the utility of thyroid ultrasound in detecting abnormalities.
- reference: PMID:10633216
reference_title: "Grey scale thyroid ultrasonography in the evaluation of patients with Graves' disease."
supports: PARTIAL
snippet: Grey scale thyroid ultrasonography in the evaluation of patients with Graves' disease.
explanation: The title and context support the use of grey scale thyroid ultrasonography for evaluating Graves' disease, aligning with the statement that thyroid ultrasound visualizes the thyroid gland and detects abnormalities.
treatments:
- name: Antithyroid Medications
description: Methimazole and propylthiouracil (PTU) to reduce thyroid hormone production.
evidence:
- reference: PMID:17154097
reference_title: "[Childhood Graves' disease]."
supports: SUPPORT
snippet: Methimazole (MMI) and propylthiouracil (PTU) have been used, however, MMI is the preferred drug treatment.
explanation: The reference confirms that both Methimazole and PTU are used as antithyroid medications to reduce thyroid hormone production in Graves' disease.
- reference: PMID:37594736
reference_title: "The Origin of Antithyroid Drugs."
supports: PARTIAL
snippet: Antithyroid drugs remain a cornerstone of thyroid therapeutics.
explanation: The reference supports the use of antithyroid medications, including Methimazole and PTU, in the treatment of hyperthyroidism associated with Graves' disease.
- reference: PMID:36740774
reference_title: "Non-thionamide antithyroid drug options in Graves' hyperthyroidism."
supports: SUPPORT
snippet: The thionamide anti-thyroid drugs namely carbimazole, methimazole, and propylthiouracil, have been the predominant therapy modality for Graves' hyperthyroidism for over 60 years.
explanation: The reference supports the use of Methimazole and PTU as primary antithyroid medications for managing Graves' disease.
treatment_term:
preferred_term: hormone modifying therapy
term:
id: MAXO:0000283
label: hormone modifying therapy
- name: Radioactive Iodine Therapy
description: Radioactive iodine is taken orally to destroy overactive thyroid cells.
evidence:
- reference: PMID:36468997
reference_title: "[Radioactive iodine in the treatment of Graves' disease: history and modern concept of radionuclide therapy]."
supports: PARTIAL
snippet: Radioactive iodine 131I is a theranostic isotope used both for diagnosis and therapy of benign thyroid diseases and thyroid cancer for 85 years.
explanation: The abstract confirms that radioactive iodine is used for therapy, including the treatment of Graves' disease, which involves destroying overactive thyroid cells.
- reference: PMID:2451239
reference_title: "Graves' disease. Manifestations and therapeutic options."
supports: SUPPORT
snippet: Radioactive iodine is the most frequently used and safest method of treatment for adults.
explanation: This reference supports the use of radioactive iodine therapy for treating Graves' disease by destroying overactive thyroid cells.
- reference: PMID:1987448
reference_title: "Graves' disease. Current concepts."
supports: SUPPORT
snippet: In most clinical situations, a strong argument can be made for iodine-131 therapy, which is safe and definitive, although posttreatment hypothyroidism and the need for lifelong thyroxine are to be expected.
explanation: The text confirms the use of radioactive iodine therapy (iodine-131) for treating Graves' disease, consistent with the statement.
treatment_term:
preferred_term: hormone modifying therapy
term:
id: MAXO:0000283
label: hormone modifying therapy
- name: Thyroidectomy
description: Surgical removal of part or all of the thyroid gland.
evidence:
- reference: PMID:35728139
reference_title: "Surgical management of Graves' disease: historical context and single institution experience."
supports: SUPPORT
snippet: 'Total thyroidectomy resulted in long-term control of thyrotoxicosis in all patients. There were no incidences of recurrent laryngeal nerve injury. One patient (1.6%) suffered permanent hypoparathyroidism. CONCLUSION: Total thyroidectomy is a safe and effective treatment for Graves'' disease.'
explanation: The study supports the statement that surgical removal of the thyroid gland, specifically total thyroidectomy, is used in the treatment of Graves' disease.
- reference: PMID:25103076
reference_title: "Volume changes in remnant thyroid tissue after thyroidectomy in Graves disease."
supports: SUPPORT
snippet: Surgery is one of the treatment choices for Graves disease.
explanation: The study indicates that thyroidectomy is one of the treatment options for Graves' disease, supporting the statement.
- reference: PMID:34243871
reference_title: "Extrathyroidal Manifestations of Thyroid Disease: Graves Eye Disease."
supports: NO_EVIDENCE
snippet: Graves disease is an autoimmune disorder...In approximately 25% of patients, an inflammatory condition, Graves eye disease (GED), affects the orbital soft tissues.
explanation: While this reference focuses on Graves eye disease, it indirectly supports the statement by discussing the broader context of Graves' disease treatment.
- reference: PMID:30180972
reference_title: "Graves' disease in children."
supports: SUPPORT
snippet: Indications for a radical treatment can arise in cases of...relapse despite prolonged medical treatment...Surgery is the radical method of treatment used in children under 5 years of age, or in cases of very large, nodular, or compressive goiters.
explanation: The study discusses the use of surgery as a treatment for Graves' disease in specific cases, supporting the statement.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
- name: Beta Blockers
description: Used to manage cardiovascular symptoms like tachycardia and palpitations.
evidence:
- reference: PMID:22975536
reference_title: "Short-term effects of β-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves' disease."
supports: SUPPORT
snippet: beta-adrenergic antagonists (beta-blockers) are often used to attenuate the hyperadrenergic symptoms of Graves' disease (GD), including palpitation.
explanation: The study confirms that beta-blockers are used to manage cardiovascular symptoms like tachycardia and palpitations in Graves' disease.
- reference: PMID:36518043
reference_title: "Ivabradine for Uncontrolled Sinus Tachycardia in Thyrotoxic Cardiomyopathy - Case Report."
supports: PARTIAL
snippet: Beta-blockers, mainly propranalol, are usually administered to control heart rate in patients with thyrotoxicosis, especially when congestive heart failure presents.
explanation: The case report supports the use of beta-blockers to control heart rate in patients with thyrotoxicosis, which includes Graves' disease.
- reference: PMID:32402541
reference_title: "Impact of surgery versus medical management on cardiovascular manifestations in Graves disease."
supports: PARTIAL
snippet: Tachyarrhythmias, including atrial fibrillation and tachycardia, improved in 85.9% of patients in the surgical group vs 66% in the medical group (P = .01).
explanation: The study indicates that both surgical and medical (which includes beta-blockers) management improves tachyarrhythmias in Graves' disease patients.
treatment_term:
preferred_term: beta adrenergic agent therapy
term:
id: MAXO:0000186
label: beta adrenergic agent therapy
- name: Corticosteroids
description: Used to reduce inflammation in severe ophthalmopathy.
evidence:
- reference: PMID:33069387
reference_title: "Treatment of Graves' ophthalmopathy."
supports: SUPPORT
snippet: Glucocorticoids at high doses are the cornerstone in moderate-severe cases.
explanation: The literature indicates that glucocorticoids (a type of corticosteroid) are a primary treatment for moderate-severe Graves' ophthalmopathy, which supports their use to reduce inflammation in severe ophthalmopathy.
- reference: PMID:29923966
reference_title: "Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye Disease."
supports: SUPPORT
snippet: Corticosteroids continue to be the primary medical therapy for TED.
explanation: Thyroid eye disease (TED) is another term for Graves' ophthalmopathy, and corticosteroids are noted as the primary medical therapy for this condition.
- reference: PMID:36272013
reference_title: "Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review."
supports: SUPPORT
snippet: Corticosteroids have been the first-line treatment for GO.
explanation: Graves' ophthalmopathy (GO) is treated primarily with corticosteroids, as indicated in the literature.
- reference: PMID:22632369
reference_title: "Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy."
supports: SUPPORT
snippet: Glucocorticoids (oral or intravenous) represent the main treatment of moderate-to-severe GO, the intravenous route being more effective.
explanation: Glucocorticoids, a type of corticosteroid, are the main treatment for moderate-to-severe Graves' ophthalmopathy, supporting their use to reduce inflammation.
treatment_term:
preferred_term: systemic corticosteroid therapy
term:
id: NCIT:C122080
label: Systemic Corticosteroid Therapy
- name: Teprotumumab
description: >-
FDA-approved anti-IGF-1R monoclonal antibody for moderate-to-severe active
thyroid eye disease. Blocks TSHR-IGF1R crosstalk in orbital fibroblasts to
reduce proptosis, diplopia, and clinical activity. Validated by the OPTIC
Phase III trial.
target_mechanisms:
- target: TSHR-IGF1R Receptor Crosstalk in Orbital Fibroblasts
evidence:
- reference: PMID:31971679
supports: SUPPORT
snippet: "Among patients with active thyroid eye disease, teprotumumab resulted in better outcomes with respect to proptosis, Clinical Activity Score, diplopia, and quality of life than placebo; serious adverse events were uncommon."
explanation: The OPTIC Phase III trial demonstrated that teprotumumab (anti-IGF-1R) significantly improved proptosis, diplopia, and quality of life compared to placebo in active thyroid eye disease.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: teprotumumab
term:
id: NCIT:C95797
label: Teprotumumab
review_notes: Graves' Disease is an autoimmune disorder that leads to hyperthyroidism, characterized by symptoms of an overactive thyroid such as weight loss, heat intolerance, and tachycardia. It can also cause specific ocular and dermatologic manifestations. Diagnosis involves a combination of biochemical tests with a high index of clinical suspicion, and treatment options vary based on severity and patient preferences.
disease_term:
preferred_term: Graves disease
term:
id: MONDO:0005364
label: Graves disease
classifications:
harrisons_chapter:
- classification_value: endocrine system disorder
- classification_value: thyroid disorder
- classification_value: autoimmune disease
Objective 1: Define core mechanisms. Objective 2: Map key molecular players (HGNC), cells (CL), tissues (UBERON), chemicals (CHEBI). Objective 3: Summarize disrupted GO processes and cellular components. Objective 4: Describe disease progression and phenotypes (HP). Objective 5: Incorporate 2023–2024 evidence with URLs/dates, statistics, and expert analyses. Objective 6: Provide ontology-anchored artifact. Objective 7: Synthesize final narrative.
Graves’ disease (GD) is an organ-specific autoimmune disorder driven predominantly by stimulatory thyrotropin receptor autoantibodies (TRAbs; mainly IgG1) that bind the thyrotropin receptor (TSHR) on thyrocytes, activating G protein–coupled signaling to increase thyroid hormone synthesis and release, and to promote thyrocyte growth (cAMP/PKA; with contributions from PI3K/AKT and MAPK cascades). Loss of tolerance arises from antigen presentation of TSHR peptides by HLA class II on antigen-presenting cells, activation of autoreactive CD4+ T cells, and CD40–CD40L-dependent B-cell help culminating in germinal-center maturation of TRAb-producing B cells; oligoclonal intrathyroidal B cells and possible epitope spreading are characteristic (July 2024; Nature Reviews Endocrinology; https://doi.org/10.1038/s41574-024-01016-5). Epidemiologically, GD prevalence is ~1.2% with female:male ~10:1 and incidence ~20–40 per 100,000/year (July 2024; Nature Reviews Endocrinology; https://doi.org/10.1038/s41574-024-01016-5) (lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 18-21).
Th subsets are dysregulated: enhanced Th1/Th17 and T follicular helper (Tfh) responses and reduced regulatory T cells (Tregs) support B-cell activation and autoantibody production; IL-17/IL-21 axes are implicated in sustaining autoimmunity and linking to clinical activity (July 2024; Nature Reviews Endocrinology; https://doi.org/10.1038/s41574-024-01016-5) (lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 21-24).
Genetic susceptibility is polygenic, with robust associations at HLA class II (e.g., HLA-DRB1), immune-regulatory loci CTLA4, PTPN22, CD40, FCRL3, and the thyroid-specific TSHR gene; epigenetic mechanisms and gut microbiome influences (dysbiosis, Th17/Treg imbalance) are recognized modifiers (Dec 2024; Reviews in Endocrine & Metabolic Disorders; https://doi.org/10.1007/s11154-023-09848-8; July 2024; Nature Reviews Endocrinology; https://doi.org/10.1038/s41574-024-01016-5) (lanzolla2024gravesdiseaselatest pages 21-24, lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 18-21).
Thyroid eye disease (TED; Graves’ orbitopathy, GO) is an extrathyroidal manifestation arising when immune responses target antigens on orbital fibroblasts (OFs), notably TSHR and insulin-like growth factor 1 receptor (IGF-1R). Functional crosstalk between TSHR and IGF-1R promotes OF proliferation, hyaluronan (HA) production, adipogenesis (CD90– OFs), and fibrosis (CD90+ OFs), producing proptosis, diplopia, and soft-tissue inflammation; b‑arrestin-1 has been proposed as a scaffold mediating receptor cooperativity (Jan 2023; Frontiers in Immunology; https://doi.org/10.3389/fimmu.2023.1062045; May 2024; Frontiers in Immunology; https://doi.org/10.3389/fimmu.2024.1392956) (cui2023areviewof pages 1-2, shu2024immunecheckpointsnew pages 11-12). TED incidence is estimated ~0.54–0.9/100,000/year in males and 2.67–3.3/100,000/year in females; 25–50% of GD patients develop TED, with ~5–6% severe disease (Jan 2023; Frontiers in Immunology; https://doi.org/10.3389/fimmu.2023.1062045) (cui2023areviewof pages 1-2).
Environmental triggers and modifiers include smoking (strongest TED risk), iodine exposure, infections/stress, postpartum immune shifts, radioiodine, and metabolic/oxidative stress; dyslipidemia has been linked to TED risk and corticosteroid responsiveness (July 2024; Nature Reviews Endocrinology; https://doi.org/10.1038/s41574-024-01016-5) (lanzolla2024gravesdiseaselatest pages 21-24, lanzolla2024gravesdiseaselatest pages 18-21).
Immune checkpoint inhibitor (ICI)–related thyroid autoimmunity provides mechanistic insight: PD‑1 blockade (and to a lesser extent CTLA‑4 blockade) precipitates destructive thyroiditis, hypothyroidism, and less often Graves’ disease, highlighting the role of checkpoints in maintaining thyroidal tolerance (May 2024; Frontiers in Oncology; https://doi.org/10.3389/fonc.2024.1381250; Mar 2024; Heliyon; https://doi.org/10.1016/j.heliyon.2024.e27077) (zhao2024theriskof pages 5-8, wang2024thyroiddysfunction(td) pages 7-9).
| Category | Item (preferred name) | Identifier (ontology/code) | Role in GD/TED (short clause) | Key supporting sources |
|---|---|---|---|---|
| Gene/Protein | TSHR (thyrotropin receptor) | HGNC:TSHR | Principal autoantigen; target of stimulating/blocking/neutral TRAbs causing cAMP-driven thyrocyte activation | (lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 18-21) |
| Gene/Protein | IGF1R (insulin-like growth factor 1 receptor) | HGNC:IGF1R | Receptor that crosstalks with TSHR to activate orbital fibroblasts, adipogenesis and HA production | (cui2023areviewof pages 1-2, shu2024immunecheckpointsnew pages 11-12, lanzolla2024gravesdiseaselatest pages 1-5) |
| Gene/Protein | CTLA4 | HGNC:CTLA4 | Immune-checkpoint gene; modulates T-cell tolerance and associated with GD susceptibility | (lanzolla2024gravesdiseaselatest pages 21-24, shu2024immunecheckpointsnew pages 11-12) |
| Gene/Protein | PTPN22 | HGNC:PTPN22 | Immune-regulatory phosphatase; genetic susceptibility locus affecting T-cell signaling | (lanzolla2024gravesdiseaselatest pages 21-24, lanzolla2024gravesdiseaselatest pages 1-5) |
| Gene/Protein | CD40 | HGNC:CD40 | B–T costimulatory receptor required for germinal center reactions and TRAb generation | (lanzolla2024gravesdiseaselatest pages 18-21, shu2024immunecheckpointsnew pages 11-12) |
| Gene/Protein | FCRL3 | HGNC:FCRL3 | B-cell–linked receptor with genetic association to GD susceptibility | (lanzolla2024gravesdiseaselatest pages 21-24, lanzolla2024gravesdiseaselatest pages 1-5) |
| Gene/Protein | HLA-DRB1 | HGNC:HLA-DRB1 | MHC class II molecule mediating antigen presentation; major susceptibility locus | (lanzolla2024gravesdiseaselatest pages 21-24, lanzolla2024gravesdiseaselatest pages 18-21) |
| Gene/Protein | FOXP3 | HGNC:FOXP3 | Master regulator of Treg identity; Treg defects linked to loss of tolerance in GD | (lanzolla2024gravesdiseaselatest pages 21-24, lanzolla2024gravesdiseaselatest pages 1-5) |
| Gene/Protein | IL6 | HGNC:IL6 | Proinflammatory cytokine that promotes orbital fibroblast activation and upregulates TSHR | (cui2023areviewof pages 1-2, lanzolla2024gravesdiseaselatest pages 18-21) |
| Gene/Protein | IL17A | HGNC:IL17A | Th17 cytokine driving inflammation and perturbing Th17/Treg balance in AITD | (lanzolla2024gravesdiseaselatest pages 21-24, lanzolla2024gravesdiseaselatest pages 1-5) |
| Gene/Protein | IL21 | HGNC:IL21 | Tfh/Th17-associated cytokine that supports B-cell differentiation and autoantibody production | (lanzolla2024gravesdiseaselatest pages 21-24, lanzolla2024gravesdiseaselatest pages 1-5) |
| Gene/Protein | PDCD1 (PD-1) | HGNC:PDCD1 | Immune-checkpoint receptor relevant to ICI-related thyroid irAEs and peripheral tolerance | (shu2024immunecheckpointsnew pages 11-12, zhao2024theriskof pages 5-8) |
| Biological Process | cAMP-mediated signaling | GO:0019933 | Primary intracellular cascade downstream of TSHR driving hormone synthesis and proliferation | (lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 18-21) |
| Biological Process | MAPK cascade | GO:0000165 | Growth/differentiation signaling downstream of TSHR/IGF1R influencing proliferation and fibrosis | (lanzolla2024gravesdiseaselatest pages 1-5, cui2023areviewof pages 1-2) |
| Biological Process | PI3K signaling | GO:0014065 | Mediates survival, adipogenesis and HA production in orbital fibroblasts | (cui2023areviewof pages 1-2, lanzolla2024gravesdiseaselatest pages 18-21) |
| Biological Process | B cell activation | GO:0042113 | Germinal-center B-cell activation producing pathogenic TRAbs | (lanzolla2024gravesdiseaselatest pages 18-21, lanzolla2024gravesdiseaselatest pages 21-24) |
| Biological Process | Germinal center formation (placeholder) | GO:0006959 | Site of affinity maturation and oligoclonal TRAb expansion (epitope spreading) | (lanzolla2024gravesdiseaselatest pages 18-21, lanzolla2024gravesdiseaselatest pages 1-5) |
| Biological Process | Adipocyte differentiation | GO:0045444 | Orbital adipogenesis underlying proptosis in TED | (cui2023areviewof pages 1-2, lanzolla2024gravesdiseaselatest pages 18-21) |
| Biological Process | Extracellular matrix organization | GO:0030198 | HA/GAG accumulation and tissue remodeling in orbit and thyroid stroma | (cui2023areviewof pages 1-2, lanzolla2024gravesdiseaselatest pages 18-21) |
| Biological Process | Hyaluronan biosynthetic process | GO:0030213 | HA synthesis by orbital fibroblasts driving edema and proptosis | (cui2023areviewof pages 1-2, lanzolla2024gravesdiseaselatest pages 18-21) |
| Biological Process | Inflammasome assembly | GO:0061952 | Drives IL-1β/IL-18 release and inflammatory cell death contributing to orbital inflammation | (cui2023areviewof pages 1-2, shu2024immunecheckpointsnew pages 11-12) |
| Biological Process | Pyroptosis | GO:0070269 | Inflammatory programmed cell death implicated in retro-orbital inflammation | (cui2023areviewof pages 1-2, shu2024immunecheckpointsnew pages 11-12) |
| Cellular Component | Plasma membrane | GO:0005886 | Location of TSHR/IGF1R where extracellular TRAbs engage receptors | (lanzolla2024gravesdiseaselatest pages 1-5, cui2023areviewof pages 1-2) |
| Cellular Component | Extracellular space | GO:0005615 | Locale of secreted TRAbs and shed TSHR subunits amplifying autoimmunity | (lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 18-21) |
| Cellular Component | Inflammasome complex | GO:0061702 | Multimeric complex that activates caspase-1 and pyroptosis signaling | (cui2023areviewof pages 1-2, shu2024immunecheckpointsnew pages 11-12) |
| Cellular Component | Cytosol | GO:0005829 | Intracellular compartment for cAMP/PKA, PI3K/AKT and MAPK mediators | (lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 18-21) |
| Cell Type | Thyrocyte | CL:0000066 | Hormone-producing epithelial cell targeted by TRAbs causing hyperfunction | (lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 18-21) |
| Cell Type | B cell | CL:0000236 | Autoantibody-producing cell driving TRAb generation | (lanzolla2024gravesdiseaselatest pages 18-21, lanzolla2024gravesdiseaselatest pages 21-24) |
| Cell Type | T follicular helper cell (Tfh) | CL:0000913 | Provides help for germinal-center B cells and TRAb affinity maturation | (lanzolla2024gravesdiseaselatest pages 21-24, lanzolla2024gravesdiseaselatest pages 18-21) |
| Cell Type | Th17 cell | CL:0000894 | Produces IL-17/IL-21 and promotes pathogenic inflammation in GD | (lanzolla2024gravesdiseaselatest pages 21-24, lanzolla2024gravesdiseaselatest pages 1-5) |
| Cell Type | Regulatory T cell (Treg) | CL:0000815 | Maintains tolerance; FOXP3+ Treg defects linked to GD onset/progression | (lanzolla2024gravesdiseaselatest pages 21-24, lanzolla2024gravesdiseaselatest pages 1-5) |
| Cell Type | Fibroblast (orbital fibroblast) | CL:0000057 | Produces HA, differentiates to adipocytes/myofibroblasts in TED | (cui2023areviewof pages 1-2, lanzolla2024gravesdiseaselatest pages 18-21) |
| Cell Type | Fibrocyte (CD34+) | CL:0002324 | Bone-marrow–derived precursor that infiltrates orbit and gives rise to OFs | (cui2023areviewof pages 1-2, shu2024immunecheckpointsnew pages 11-12) |
| Anatomical | Thyroid gland | UBERON:0002046 | Primary organ affected by TRAb-mediated hyperthyroidism | (lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 18-21) |
| Anatomical | Orbit | UBERON:0001651 | Site of TED pathology: OF activation, GAG deposition, adipogenesis/fibrosis | (cui2023areviewof pages 1-2, lanzolla2024gravesdiseaselatest pages 18-21) |
| Anatomical | Extraocular muscle | UBERON:0001134 | Muscle enlargement and fibrosis cause diplopia and motility restriction in TED | (cui2023areviewof pages 1-2, lanzolla2024gravesdiseaselatest pages 18-21) |
| Chemical Entity | cAMP | CHEBI:17489 | Second messenger downstream of TSHR driving hormone synthesis and proliferation | (lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 18-21) |
| Chemical Entity | Hyaluronan (HA) | CHEBI:18064 | ECM GAG accumulating in orbit producing edema and proptosis | (cui2023areviewof pages 1-2, lanzolla2024gravesdiseaselatest pages 18-21) |
| Chemical Entity | Iodine | CHEBI:24858 | Environmental modifier; excess can trigger/augment autoimmune thyroid disease | (lanzolla2024gravesdiseaselatest pages 18-21, lanzolla2024gravesdiseaselatest pages 1-5) |
| Chemical Entity | Selenium | CHEBI:27568 | Antioxidant micronutrient influencing immune responses and GO severity | (lanzolla2024gravesdiseaselatest pages 21-24, lanzolla2024gravesdiseaselatest pages 18-21) |
| Chemical Entity | Thyroxine (T4) | CHEBI:18332 | Main circulating thyroid hormone elevated in GD (systemic mediator of phenotype) | (lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 18-21) |
| Chemical Entity | Triiodothyronine (T3) | CHEBI:28775 | Active thyroid hormone increased in thyrotoxicosis | (lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 18-21) |
| Chemical Entity | Teprotumumab | (ID: blank) | Anti-IGF1R monoclonal antibody; approved targeted therapy for moderate–severe TED | (cui2023areviewof pages 1-2, lanzolla2024gravesdiseaselatest pages 18-21) |
| Chemical Entity | Rituximab | (ID: blank) | Anti-CD20 B-cell depleting antibody used in trials/selected clinical use for GD/GO | (viola2025graves’diseaseis pages 11-13, lanzolla2024gravesdiseaselatest pages 18-21) |
Table: Compact ontology-anchored table listing key genes, processes, compartments, cell types, anatomical sites and chemical entities implicated in Graves' disease and thyroid eye disease, with short mechanistic roles and primary supporting sources (2023–2024 reviews).
1) Genetic/epigenetic predisposition plus environmental triggers (e.g., smoking, iodine) initiate antigen presentation of TSHR peptides via HLA‑DR to autoreactive CD4+ T cells. 2) Tfh help and CD40–CD40L costimulation drive B-cell activation and germinal-center maturation to produce high-affinity TRAbs. 3) TSAb stimulate TSHR on thyrocytes activating cAMP/PKA and growth pathways (PI3K/AKT, MAPK), causing thyrotoxicosis and goiter. 4) In a subset, autoreactivity extends to orbital fibroblasts expressing TSHR and IGF‑1R; receptor crosstalk plus cytokine milieu (e.g., IL‑6, Th17 signals) promotes HA deposition, adipogenesis (CD90– OFs), and fibrosis (CD90+ OFs), driving TED. 5) Chronicity features epitope spreading and fluctuating TRAb titers; external modifiers (radioiodine, dyslipidemia) influence TED risk and activity (July 2024; Nature Reviews Endocrinology; Jan 2023; Frontiers in Immunology) (lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 18-21, cui2023areviewof pages 1-2, lanzolla2024gravesdiseaselatest pages 21-24).
GD pathophysiology reflects a canonical model of loss of tolerance to TSHR with Th1/Th17/Tfh–B-cell collaboration, yielding TSAb-mediated hyperthyroidism through cAMP/PKA and growth signaling. Genetic susceptibility (HLA, CTLA4, PTPN22, CD40, FCRL3, TSHR), environmental modifiers (e.g., smoking, iodine), and gut dysbiosis shape disease risk and expression. TED emerges from TSHR–IGF‑1R-driven OF activation, HA accumulation, adipogenesis, and fibrosis. Translationally, TRAb assays underpin precision diagnosis, risk stratification in pregnancy, and prognostication, while IGF‑1R inhibition (teprotumumab) and emerging CD40/TSHR-targeted therapies exemplify mechanism-based interventions. The expanded experience with ICI-related thyroiditis/hypothyroidism illuminates checkpoint roles in thyroidal tolerance and provides quantitative risk benchmarks for modern oncology care (lanzolla2024gravesdiseaselatest pages 1-5, lanzolla2024gravesdiseaselatest pages 21-24, lanzolla2024gravesdiseaselatest pages 18-21, cui2023areviewof pages 1-2, shu2024immunecheckpointsnew pages 11-12, kalra2024bestpracticesin pages 7-9, zhao2024theriskof pages 5-8, wang2024thyroiddysfunction(td) pages 7-9).
References
(lanzolla2024gravesdiseaselatest pages 1-5): Giulia Lanzolla, Michele Marinò, and Francesca Menconi. Graves disease: latest understanding of pathogenesis and treatment options. Nature reviews. Endocrinology, 20:647-660, Jul 2024. URL: https://doi.org/10.1038/s41574-024-01016-5, doi:10.1038/s41574-024-01016-5. This article has 72 citations.
(lanzolla2024gravesdiseaselatest pages 18-21): Giulia Lanzolla, Michele Marinò, and Francesca Menconi. Graves disease: latest understanding of pathogenesis and treatment options. Nature reviews. Endocrinology, 20:647-660, Jul 2024. URL: https://doi.org/10.1038/s41574-024-01016-5, doi:10.1038/s41574-024-01016-5. This article has 72 citations.
(lanzolla2024gravesdiseaselatest pages 21-24): Giulia Lanzolla, Michele Marinò, and Francesca Menconi. Graves disease: latest understanding of pathogenesis and treatment options. Nature reviews. Endocrinology, 20:647-660, Jul 2024. URL: https://doi.org/10.1038/s41574-024-01016-5, doi:10.1038/s41574-024-01016-5. This article has 72 citations.
(cui2023areviewof pages 1-2): Xuejiao Cui, Futao Wang, and Cong Liu. A review of tshr- and igf-1r-related pathogenesis and treatment of graves’ orbitopathy. Frontiers in Immunology, Jan 2023. URL: https://doi.org/10.3389/fimmu.2023.1062045, doi:10.3389/fimmu.2023.1062045. This article has 50 citations and is from a peer-reviewed journal.
(shu2024immunecheckpointsnew pages 11-12): Xingyi Shu, Yuchao Shao, Yuqing Chen, Chengcheng Zeng, Xiao Huang, and Ruili Wei. Immune checkpoints: new insights into the pathogenesis of thyroid eye disease. Frontiers in Immunology, May 2024. URL: https://doi.org/10.3389/fimmu.2024.1392956, doi:10.3389/fimmu.2024.1392956. This article has 16 citations and is from a peer-reviewed journal.
(zhao2024theriskof pages 5-8): Pengfei Zhao, Ting Zhao, Lihong Yu, Wenming Ma, Wenyu Liu, and Chenning Zhang. The risk of endocrine immune-related adverse events induced by pd-1 inhibitors in cancer patients: a systematic review and meta-analysis. Frontiers in Oncology, May 2024. URL: https://doi.org/10.3389/fonc.2024.1381250, doi:10.3389/fonc.2024.1381250. This article has 9 citations and is from a poor quality or predatory journal.
(wang2024thyroiddysfunction(td) pages 7-9): Yanling Wang, Xiaoxuan Yang, Jia Ma, Shenglan Chen, Ping Gong, and Ping Dai. Thyroid dysfunction (td) induced by pd-1/pd-l1 inhibitors in advanced lung cancer. Heliyon, 10:e27077, Mar 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e27077, doi:10.1016/j.heliyon.2024.e27077. This article has 4 citations and is from a peer-reviewed journal.
(viola2025graves’diseaseis pages 11-13): Nicola Viola, Alessandro Colleo, Mauro Casula, Chiara Mura, Francesco Boi, and Giulia Lanzolla. Graves’ disease: is it time for targeted therapy? a narrative review. Medicina, 61:500, Mar 2025. URL: https://doi.org/10.3390/medicina61030500, doi:10.3390/medicina61030500. This article has 5 citations and is from a poor quality or predatory journal.
(gong2025riskfactorsand pages 1-2): Wenwen Gong, Erhan Zheng, Minchao Liu, Yaliang Han, Zhaohui Lyu, and Qinghua Guo. Risk factors and outcomes of thyroid immune-related adverse events following pd-1/pd-l1 inhibitors treatment in a large tertiary chinese center. BMC Endocrine Disorders, Jul 2025. URL: https://doi.org/10.1186/s12902-025-01986-1, doi:10.1186/s12902-025-01986-1. This article has 0 citations and is from a peer-reviewed journal.
(kalra2024bestpracticesin pages 7-9): Sanjay Kalra, Shahjada Selim, Dina Shrestha, Noel Somasundaram, Syed Abbas Raza, Manash P. Baruah, Saptarshi Bhattacharya, Sharvil Gadve, Ganapathi Bantwal, and Rakesh Sahay. Best practices in the laboratory diagnosis, prognostication, prediction, and monitoring of graves’ disease: role of trabs. BMC Endocrine Disorders, Dec 2024. URL: https://doi.org/10.1186/s12902-024-01809-9, doi:10.1186/s12902-024-01809-9. This article has 2 citations and is from a peer-reviewed journal.